Background. The uraemic retention solutes p-cresylsulphate (pCS) and p-cresylglucuronide (pCG), two conjugates of pcresol, were never determined simultaneously. In the present paper, a high-performance liquid chromatography (HPLC) method was developed and used to quantify both compounds in parallel in an in vivo observational study and their in vitro effect was evaluated by flow cytometry. Methods. pCS and pCG were determined in serum. For the validation specificity, linearity, recovery, precision and the quantification limit were evaluated. In vivo, concentrations of both compounds were determined in 15 controls and 77 haemodialysis patients, as well as protein binding in the dialysed group and the reduction ratios during haemodiafiltration. In addition, the in vitro effect of the solutes on leucocyte free radical production at measured concentrations was assessed. Results. A fast and accurate HPLC method was developed to simultaneously quantify pCS and pCG. Both conjugates are retained in uraemia with a substantially higher total serum pCS in comparison to pCG (31.4 6 15.8 versus 7.3 6 6.5 mg/L) but also a substantial difference in protein binding (92.4 6 3.0 versus 8.3 6 4.4%) and in reduction ratio during post-dilution haemodiafiltration (37.4 6 7.1 versus 78.6 6 6.4%). pCG per se has no effect on leucocyte 
Introduction
Chronic kidney disease (CKD) is characterized by the progressive accumulation of a host of retention solutes [1] , which have been linked to several uraemic complications [2, 3] . Recently, protein-bound uraemic solutes, with the phenols and indoles as most important representatives, have come more and more into focus [4] . Among the phenols, conceptual thinking about retention and toxicity underwent a profound shift of paradigm when it appeared that not p-cresol, as originally believed, but its conjugates p-cresylsulphate (pCS) and p-cresylglucuronide (pCG) were retained in uraemia [5, 6] . Subsequently, it was demonstrated that pCS activated leucocytes and deteriorated endothelial function, suggesting an association with vascular damage [7, 8] . Clinical outcome studies confirmed an association with cardiovascular risk in CKD 2-5 [9] and even in stable angina patients with early renal failure [10] .
pCG, on the other hand, has, to the best of our knowledge, never been quantified directly and has also not been assessed for its biological impact.
The scope of this study was (i) to develop and validate a simple, accurate reversed-phase high-performance liquid chromatography (RP-HPLC) method for the simultaneous determination of pCS and pCG; (ii) to determine in a haemodialysis population the total and free concentration and the corresponding protein binding of pCS and pCG; (iii) to compare dialytic removal of pCS and pCG with each other and to that of urea and (iv) to assess the in vitro impact on leucocyte oxidative burst activity of pCS and pCG alone and of a combination of both.
Materials and methods

Chemicals and reagents
pCS was synthesized according to Feigenbaum and Neuberg as a potassium salt [11] . pCG was synthesized from protected glucuronyl-trichloroacetimidate and p-cresol using a protocol similar to the one described by Van der Eycken et al. [12] . All intermediate products of pCG synthesis were eliminated by flash chromatography over silica gel; the final product was further purified and isolated as ammonium salt using amberlyte IR120 ion exchange resin. The purity of both pCS and pCG was checked by liquid chromatographymass spectrometry and nuclear magnetic resonance.
All other reagents used were of analytical grade.
Sample collection
The analyses performed on serum samples were collected in blood venules without anticoagulants. For the validation experiments, serum of three healthy volunteers and pre-dialysis serum of three haemodialysis patients were pooled.
For the analytical comparison of controls versus dialysed patients, serum samples from 15 healthy volunteers (age: 26 AE 4 years, male/female: 11/4) and from 77 patients on haemodialysis (age: 69 AE 14 years; male/female: 50/ 27; on dialysis since 35 AE 27 months; diabetes: 45%) immediately before the start of a midweek dialysis session were collected.
For the removal data, pre-dialysis and post-dialysis serum samples were collected during a midweek post-dilution haemodiafiltration session (blood flow: 300 mL/min, dialysate flow: 800 mL/min, substitution flow: 75 mL/ min and dialysis duration: 251 AE 15 min) in 14 patients (age: 70 AE 11 years; male/female: 11/3; on dialysis since 40 AE 19 months; diabetes: 45%). Haemodiafiltration was selected as extracorporeal renal replacement strategy since previous acute and longitudinal studies revealed this strategy as optimal for removal of protein-bound and other solutes [13] [14] [15] . Reduction ratios (RR, %) ÂÀ C pre-dialysis À C post-dialysis ÁÀ C pre-dialysis Á 3100 Ã of urea, pCS and pCG were calculated.
All serum samples were stored at À80°C until analysis. For the in vitro studies, heparinized whole blood samples (sodium heparin Vacutainerä tubes, BD) were collected from eight healthy volunteers. Those who smoked, were pregnant, had an infection or were on medication were excluded.
The study was approved by the local Ethics Committee and conducted in accordance with the principles of the Declaration of Helsinki and rules of Good Clinical Practice. Written informed consent was obtained from all participants.
HPLC analyses
Instrumentation. HPLC analyses were performed using a Waters Alliance 2695 device (Waters, Zellik, Belgium) connected with a Waters 2475 fluorescence detector. The separation was carried out at room temperature on a reversed-phase Ultrasphere ODS column (150 3 4.6 mm, 5-lm particle size; Beckman Instruments, Fullerton, CA) with an Ultrasphere ODS guard column (45 3 4.6 mm, 5-lm article size; Beckman Instruments). The chromatographic separation consisted of a linear gradient of methanol and ammonium formate buffer (50 mM, pH 3.0) from 35 to 70% methanol in 15 min at a flow rate of 1 mL/min. The fluorescence detector was set at k ex 265 nm/k em 290 nm. Data analyses were done using Empower 2 software (Waters).
Sample preparation and calculations. Determination of total and free concentrations.-To measure the total serum concentration, samples were diluted from one to six with HPLC water followed by heating at 95°C during 30 min. After cooling down (10 min on ice), samples were filtered through a CentrifreeÒ filter (Millipore, Billerica, MA). The ultrafiltrate (60 lL) was injected onto the column. To determine the free fraction, untreated serum samples were filtered through CentrifreeÒ prior to heating.
Fluorescence emission and excitation spectra were recorded from standard solutions and from control and uraemic samples, allowing to select the optimal wavelengths and to exclude co-eluted interferences.
Calibration standards.-Aqueous solutions containing a mixture of pCS and pCG were used to obtain calibration curves in the working range of 0.5-50.0 mg/L. The standard solutions were treated in the same way as serum samples. Peak areas were plotted in function of concentrations and all concentrations were expressed as milligram per litre.
Recovery experiments.-Pooled serum of healthy volunteers was spiked with two concentrations (9.0 and 48.0 mg/L) of both pCS and pCG. Eight replicates of both concentrations were tested. Recovery was calculated as follows: (final concentration À initial concentration)/added concentration.
Precision experiments.-The intra-day and inter-day precisions were evaluated in pooled serum of healthy donors and pooled serum of haemodialysis patients. The precision was estimated in both samples eight times on the same day (intra-day precision) and on two replicates on four separate days (inter-day precision). The precision is expressed as relative standard deviation (RSD, %).
Limit of quantification (LOQ).-According to ICH guidelines, LOQ was determined based on the SD of the response and slope of a calibration curve obtained by serial dilutions of serum samples (LOQ ¼ 10 r/S, where r is the SD of the response and S is the slope of the calibration curve) [16] .
pCS and pCG determination and in vitro effect
Routine laboratory analyses
Total protein content and urea were measured by standard laboratory methods.
In vitro studies Stock solutions. Stock solutions (103) of pCS, of pCG and of both pCS and pCG were prepared in saline (Baxter, Lessines, Belgium) according to a standardized approach for in vitro research in uraemia [17] . The concentrations at which both compounds were added to the test system were twice the maxima measured in the present clinical study on 77 haemodialysis patients in analogy with our previous study on pCS [7] . Since pCS and pCG were, respectively, obtained as a potassium and an ammonium salt, not only saline but also KCl and NH4Cl control solutions (Sigma-Aldrich Co, St Louis, MO), at equimolar potassium and ammonium concentrations, were tested.
Oxidative burst activity. After a 10-min incubation period of the whole blood of healthy volunteers at 37°C with saline (control), KCl alone, NH4Cl alone, KCl and NH4Cl combined, pCS alone, pCG alone or pCG and pCS combined, leucocyte oxidative burst activity was evaluated using the Burst test (PhagoburstÒ; Orpegen Pharma, Heidelberg, Germany), as described previously [7] . Oxidative burst activity was measured by flow cytometry at baseline, after stimulation with N-formyl-methionineleucine-phenylalanine (fMLP; 0.83 lM), Escherichia coli (E. coli) (1.66 3 10 8 cells/mL) and phorbol-12-myristate-13-acetate (PMA; 1.35 lM). Monocytes, granulocytes and lymphocytes were gated separately in the light scatter dot plot according to size (forward scatter) and granularity (side scatter). For the baseline status and after fMLP stimulation, the percentage (%) of rhodamine-positive cells was assessed. Since the majority of cells became rhodamine positive after stimulation with E. coli or PMA (>85%), for these two stimuli, the mean fluorescence intensity (MFI) per cell was evaluated.
Statistics
Statistical evaluation was performed with Prism 4.0 (GraphPad Software Inc., San Diego, CA). Data are shown as mean AE SD (validation, biochemical and removal results) and as mean AE SEM (in vitro results). Data were checked for normality with Kolmogorov-Smirnov test. Parametric statistical tests were used for correlations via the Pearson correlation coefficient, for differences between subjects the unpaired t-test and for evaluation of removal data analysis of variance with post hoc analysis. In case data were non-normally distributed, the non-parametric equivalent was used. A P-value of <0.05 was considered significant.
Results
Validation
Specificity and selectivity. Figure 1 shows the chromatograms of a standard solution of pCS and pCG (10.0 mg/L) and of serum of a haemodialysis patient (pCS: 29.9 mg/L and pCG: 6.8 mg/L). The method demonstrated excellent chromatographic specificity with baseline separation of pCS and pCG and no interference with other components at the retention times of pCS and pCG (4.4 and 5.4 min, respectively), as illustrated in fluorescence spectra (Figure 2 ).
Linearity. Eight independent replicates of calibration samples were injected and linearity was obtained with an overall coefficient of determination (R 2 ) of !0.9999 for both pCS and pCG. The relative residual deviation was <7.1% for all calibrators. The RSD of the slopes was <0.8%.
Recovery. The recovery rates for pCS were 95.7 AE 0.8% (9.0 mg/L) and 96.5 AE 1.3% (48.0 mg/L); for pCG, they were 99.3 AE 0.8% (9.0 mg/L) and 98.8 AE 1.2% (48.0 mg/L).
Precision. The intra-day precision RSDs for both pCS and pCG were <2.0% in pooled serum from healthy donors (mean pCS: 2.0 mg/L and mean pCG: 0.3 mg/L) and <0.9% in pooled serum of haemodialysis patients (mean pCS: 31.6 mg/L and mean pCG: 5.0 mg/L). The inter-day precision for both pCS and pCG was <3.0% in pooled serum from healthy donors and <2.0% in pooled serum from haemodialysis patients.
Limit of quantification. LOQ is 0.25 mg/L for both pCS and pCG.
In vivo data
The total serum levels of pCS and pCG in healthy volunteers (n ¼ 15) were 2.87 AE 1.71 and 0.35 AE 0.03 mg/L, respectively. The free concentration levels, however, could not be quantified because they were below the quantification limit.
Midweek pre-dialysis serum samples were collected from 77 uraemic patients. The mean total protein content of the serum samples was 60.5 AE 5.7 g/L.
The total, free and bound concentrations of pCS and pCG are illustrated in Table 1 . The total mean concentration of pCS is substantially higher than that of pCG. In contrast, the free mean concentration of pCG is proportionally higher than that of pCS. The conjugates pCS and pCG show a markedly different percentage protein binding with a mean value of 92.4 AE 3.0% for pCS but only 8.3 AE 4.4% for pCG.
The total serum levels of pCS and pCG were substantially higher in dialysis patients compared to healthy volunteers with a ratio of uraemic versus normal total concentration of~10 for pCS and~20 for pCG.
The total, free and bound concentrations of pCS and pCG were intermutually correlated ( Figure 3 , P < 0.001). Also, the protein binding of both conjugates, although markedly different, showed a weak but significant correlation ( Figure 3 , r ¼ 0.40, P < 0.001).
The correlations of free versus total concentration, of bound versus total concentration and of bound versus free concentration for pCS and pCG, respectively, are illustrated in Figure 4 . All these correlations were highly significant. There was, however, no significant association between pCS and pCG binding (%) and their respective total concentration (data not shown).
A correlation index of 1.0 for bound versus total pCS and for free versus total pCG possibly reflects that the major fraction of these molecules is, respectively, bound (pCS) and free (pCG).
We found no relation between pre-dialysis pCS/pCG concentration (total, free, bound and per cent binding) and age, time on dialysis, total protein concentration, gender or presence/absence of diabetes.
Removal by haemodiafiltration
Pre-dialysis and post-dialysis serum samples were collected from 14 haemodialysis patients during a midweek post-dilution haemodiafiltration session: RR of pCS was low (37.4 AE 7.1%) which corresponds to~50% of the RR of urea (77.0 AE 8.5%) and that of pCG (78.6 AE 6.4%).
In vitro data
The effect of pCG, pCS and the combination of both compounds on the oxidative burst activity is illustrated in Figure 5 .
None of the salt control solutions (KCl, NH4Cl or KCl 1 NH4Cl) showed a significant difference versus saline (data not shown), therefore only saline control data are presented. PCG by itself had no impact on the respiratory burst The left panels represent a standard solution; the right panels represent a uraemic serum sample; the figures above are fluorescence emission spectra with maxima at 284 and 293 nm, respectively, for pCS and pCG; the lower figures are fluorescence excitation spectra with maxima at 264 and 268 nm, respectively, for pCS and pCG.
pCS and pCG determination and in vitro effect 2391 activity irrespective of the leucocyte subtype. In contrast, pCS increased leucocyte activity in all leucocyte types at baseline (P < 0.01). In addition, it also caused a further enhancement of activation after stimulation with fMLP in lymphocytes (P < 0.05) and with E. coli and PMA in monocytes and granulocytes (P < 0.05). The combination of pCS and pCG had a stimulatory effect versus control for all leucocyte types and in all experimental conditions except for lymphocytes after E. coli. In addition, the combination of both compounds had a stronger activating effect compared to pCS alone on all cell types at baseline and also on fMLP-stimulated granulocytes.
In summary, whereas the immune stimulating effect of pCS is confirmed [7] , the combination of pCS and pCG has an extra pro-inflammatory impact, although pCG as such appears to be inert.
Discussion
In this study, we developed a simple, fast and accurate HPLC method allowing simultaneous determination of pCS and pCG in serum, with an aim to determine their concentrations in both controls and dialysis patients, their removal by dialysis and the biological impact of both compounds alone and in combination at concentrations observed in the uraemic condition. The main findings are as follows:
(1) serum concentrations of pCS and pCG are markedly increased in uraemic patients compared to healthy subjects; (2) the total pre-dialysis concentration of pCS is substantially higher than that of pCG. The free concentration of pCS, on the contrary, is lower than that of pCG (Table 1) ; (3) consequently, the protein binding of the two conjugates is markedly different with a high binding for pCS (92.4 AE 3.0%) and a low binding for pCG (8.3 AE 4.4%) ( Table 1) ; (4) the reduction ratio of pCS during post-dilution haemodiafiltration is only approximately half that of urea and pCG. The reduction ratio of pCG and urea does not differ and (5) in spite of pCG being inert regarding leucocyte free radical production, it adds to the pro-inflammatory effect of pCS when tested simultaneously ( Figure 5 ).
The finding of a cumulative effect of two uraemic retention solutes together, while only one of these two showed biological impact as such, has to our opinion rarely if ever been reported. In general, the effect of uraemic solutes as well as other compounds retained in the body is studied for one single molecule on its own, to evaluate a possible contribution to the 'net' biological or clinical status of the patient. In vivo, however, several solutes which can interfere are present together. Whereas it previously has been shown that some uraemic retention solutes, such as the guanidino compounds, could induce the production of other solutes, such as tumour necrosis factor-a [18] , the data here show a synergism among solutes. It is of note that in this case, it concerns structurally related compounds originated from the same mother compound p-cresol. Bringing both compounds together, which is more reminiscent to the in vivo reality, increases the molar concentration of cresyl-homologues, suggesting that it is the cresyl part that is responsible for the biological effect and that the naturally occurring detoxification (sulphatation and glucuronidation) does not completely neutralize a potential biological impact. Likewise, several noxious biological effects have been attributed to another conjugate, indoxylsulphate (IS) [19] [20] [21] [22] [23] [24] [25] . Because of the pro-inflammatory character of the conjugates and the possible link with cardiovascular risk, it would be of great interest in future to check the concentration levels of both conjugates in patients with different stages of CKD.
It is important to discuss the value of the presently described HPLC method and its place in the analysis of uraemic toxicity, especially vis-a-vis other emerging strategies, e.g. metabolomics. However, the latter essentially allows the evaluation of a large number of compounds, to identify those and if possible, detect unknown waste products [26, 27] . The cost and need for complex biostatistical analysis makes this option less suited for a high-throughput approach. With the presently described method, we focus on two molecules and their mutual relationship. The presently used method is better suited for analysis of a large number of samples, e.g. for kinetic or epidemiological studies.
Heat denaturation was selected as the deproteinization method for serum samples [28] . There also exists other deproteinization methods like acid hydrolysis and organic solvent (e.g. methanol) extraction. Both techniques could not be applied in our analytical set-up since acid causes deconjugation and organic solvent results in broad nonreproducible peaks. However, we are aware of the fact that heat deproteinization is not suitable for all components (e.g. thermolabile structures).
The quantitative determination of pCS is already described by two other research groups [6, 29] . Like our method, pCS was analysed with RP-HPLC. However, they used other deproteinization methods: methanol extraction [6] and sodium octanoate competition [29] . Unfortunately, we are not able to make comparisons with our method since they only measured pCS. So we cannot predict if these methods can extract pCG and if they are able to separate the conjugates, pCS and pCG. (Table 1) . To the best of our knowledge, for pCG, no direct quantification data are available. Only one publication reported calculated pCG concentrations [5] , which were, however, substantially lower compared to our present data, probably due to the indirect approach. The total concentration of pCS is largely superior to that of pCG, implicating that sulphatation is the main conjugation pathway of p-cresol in the human organism. We want to stress that concentration of a given solute is not only the result of generation but also of kinetic behaviour. On the other hand, the argument that clearance is extremely complex, especially if one takes into account that the relation between glomerular, tubular and metabolic clearance might be different per individual compound and even per patient, whereas each contributing part might be difficult to define. Considering this point of view, the kinetics of both conjugates should be further explored in depth.
We can only speculate on the reasons for the reported differences in protein binding between both compounds, but this could be attributed to charge, steric configuration, hydrophilicity/hydrophobicity, polarity, binding site or even binding protein. Some of these physico-chemical properties might also explain why pCS as such has an effect on leucocytes but pCG has not, while the two compounds together are synergistic.
The reduction ratio of pCS during post-dilution haemodiafiltration is lower than that of urea (37.4 AE 7.1 versus 77.0 AE 8.5%), which is in accordance with results of previous removal studies [13, 15] . The fact that pCS is difficult to remove, even during a highly efficient dialysis strategy, is probably due to its high level of protein binding. Reduction ratio of pCG (78.6 AE 6.4%) is twice that of pCS and is similar to that of urea (77.0 AE 8.5%). Of note, also, other protein-bound compounds with low degrees of protein binding, such as hippuric acid, tend to show a removal pattern comparable to that of urea [13, 15] . Thus, pCG behaves in a similar way as the water-soluble compounds.
As IS is generated via a similar metabolic pathway as p-cresol, however, with tryptophan and indole as precursors [31] , extrapolating our findings to these indoles, would make one expect a potential role for indoxylglucuronide (IG) as well. However, as with pCG, data on IG are scarce. In parallel with our findings, Niwa et al. [32] also observed that IS was more protein bound as compared with IG and had a higher total pre-dialysis concentration. In further agreement with our data, removal of IS during dialysis was lower than that of IG [32, 33] .
The biological consequences of retention of the proteinbound solutes have been well described [4] . Protein-bound solutes, especially pCS and IS, result in activation of leucocytes which is also demonstrated in this publication ( Figure 5 ) and these properties have been linked to microinflammation, malnutrition and atherosclerosis [34] . Combined with their ability to directly damage the endothelium [8] and to cause smooth muscle cell proliferation [19] , these solutes are associated with the development of cardiovascular disease in the CKD population [9, 10, 20, 35] . Hence, it is conceivable that enhancing the removal and/or decreasing the concentration of these protein-bound solutes might improve patient outcomes, as has been suggested for progression of renal dysfunction [36, 37] and even survival [38] . Our data show that more importantly than considering single compounds, families of solutes might be taken into account. On the other hand, within one family, removal pattern during dialysis might differ among compounds, resulting in shifts of their relationship during the procedure. We suggest that our new methodological approach might help to evaluate this interference more in depth as well as the kinetics behind it.
In conclusion, both serum levels of pCS and pCG are increased in uraemia. Both conjugates show a substantial difference in protein binding resulting in a different behaviour during dialysis. Biologically, both conjugates are synergistic in activating leucocytes and thus should be considered together rather than as separate entities.
